Key facts for KBLI 21011
The essentials a foreign investor needs to know before reading the rest of this page.
The essentials a foreign investor needs to know before reading the rest of this page.
100% foreign ownership permitted via PT PMA. KBLI 21011 is not on Indonesia's closed, conditional, SME-reserved or partnership-required schedules under Pres. Reg. 10/2021.
Default minimum paid-up capital: IDR 2.5 billion (~USD 160K) under BKPM Reg. 5/2025 (effective Oct 2025) — applies unless a sector regulator sets a higher figure for this activity. The often-cited IDR 10 billion is the total investment commitment per KBLI realised over time via quarterly LKPM reports, not required upfront.
High-risk activity — requires NIB + full Operating License (Izin) to operate commercially. NIB alone enables only the preparation stage; an Operating License must be obtained before invoicing or production starts.
Statutory licensing turnaround: 7 days once we submit the application — on top of the 2–3 weeks for PT PMA incorporation. We coordinate the full sequence end-to-end.
Issuing authority for PMA: Menteri/Kepala Badan — specific to foreign-owned entities under this KBLI.
BPOM registration mandatory: a separate Indonesian FDA marketing authorization (NIE) is required before any product is marketed. Facility must be CPOB-certified.
Ongoing reporting: quarterly LKPM (Investment Activity Report) to BKPM plus 13 sector-specific obligations. We file these on your behalf as part of monthly compliance — you stay out of the OSS portal entirely.
Diperbarui terakhir · Bersumber dari OSS Indonesia
This group includes the manufacturing and processing of medicinal materials, auxiliary materials, and packaging materials for humans, derived from chemical substances, natural materials, animals, and plants, including those from biological sources, such as medicinal products, antisera, and other blood fractions, vaccines, and homeopathic preparations. It includes the active pharmaceutical ingredient industry (antibiotics, vitamins, salicylic acid, and o-acetylsalicylic acid, among others) for pharmacological materials in the pharmaceutical industry, blood processing, pure chemical sugar industry, gland processing, gland extraction industry, and others.
Regulasi BUPM (Bidang Usaha Penanaman Modal) Indonesia menempatkan kode ini dalam salah satu dari lima kategori. Untuk perusahaan dengan pemegang saham WNI, batasan investasi asing dan ketentuan khusus PMA tidak berlaku — aturan di bawah mencakup yang relevan untuk operator lokal.
KBLI 21011 tidak memiliki batasan investasi untuk perusahaan milik Indonesia. PT lokal dengan pemegang saham WNI 100% dapat beroperasi di kegiatan ini secara langsung. Persyaratan perizinan di bawah berlaku seragam tanpa memandang nasionalitas modal.
Konteks sektor yang berlaku untuk KBLI 21011 di luar proses OSS umum. Konfirmasi dengan kementerian terkait sebelum komitmen modal.
Indonesia requires BPJPH Halal certification for an expanding range of consumer-product categories. This KBLI's activities fall in scope — see what's required and when.
OTC pharmaceuticals must hold Halal certification by October 2029; prescription drugs follow by 2034. The bar for pharma is high — every excipient, gelatin source, and processing aid must trace back to Halal-certified suppliers. Plan an 8-12 month certification project. We coordinate BPJPH alongside the BPOM marketing authorisation that any pharma product needs anyway.
Review your formulation, supply chain, and facility against BPJPH criteria. Identify ingredients or processes that need swapping.
An accredited Halal Inspection Body (LPPOM-MUI is the largest) audits the facility and reviews documentation.
The Halal certificate is issued under the BPJPH register and the Halal label can be applied to packaging.
Emerhub is a corporate-services provider in Indonesia. We do the legal and regulatory legwork for foreign investors so you can focus on the business itself. Here's what the engagement looks like.
Specific permits, application requirements and ongoing obligations vary by business scale and the sub-activity within this KBLI. We file these on your behalf — this section is for transparency on what we'll be handling. Switch between scales below; by default we show Large (the PMA scale).
Dokumen dan kapabilitas yang harus dipenuhi pada saat pendaftaran
Kewajiban kepatuhan dan pelaporan selama operasional
Otoritas yang menerbitkan izin tergantung pada situasi Anda.
| Otoritas | Berlaku saat |
|---|---|
| Menteri/Kepala Badan | Seluruhnya |
| Menteri/Kepala Badan | PMA |
PB UMKU permits sit on top of the main NIB and Sertifikat Standar — each is issued by a different ministry, and only when a specific operational activity is performed. This KBLI carries 3 candidate permits across 2 regulators; most operations only need a handful. Emerhub maps your operation to the exact set, files them, and tracks renewals.
BPOM (National Agency of Drug & Food Control). Applies to drugs, processed food, traditional medicine, cosmetics, and health supplements — produced, imported, repackaged, or distributed for human consumption. BPOM is the gating regulator; product registration is required before any commercial sale.
Ministry of Industry. Applies to specific manufacturing activities — basic chemicals, optical/magnetic media, regulated industrial materials — that need a Ministry of Industry compliance certificate beyond the standard NIB.

We confirm KBLI 21011 is the right primary code for your business, advise on secondary codes you may also need, and finalize the holding structure with you before any filing.
We draft the Articles of Association before a notary, register the entity with the Ministry of Law & Human Rights (Kemenkumham), and obtain the company's tax ID (NPWP). Under BKPM Reg. 5/2025, paid-up capital is IDR 2.5 billion (~USD 160K) — the cash actually deposited at incorporation. The IDR 10 billion+ figure many sources still cite is the total investment commitment per KBLI, realised over time via your LKPM reports.
We file the OSS application with KBLI 21011 as your primary business activity, complete the risk-based assessment, and collect the NIB (Business Identification Number) for you — typically within hours of submission. You don't need to touch the OSS portal.
NIB is issued for the preparation stage. Commercial operation requires a full Operating License (Izin) issued by the competent ministry after a substantive review of the operator's capability, facility, and compliance. Operating with NIB alone exposes the entity to penalties, blacklisting, and contract invalidation. We prepare the application bundle, liaise with the competent ministry, and chase issuance through to the certificate. Statutory turnaround: 7 business days — real-world timing typically runs longer when site inspections or additional clarifications are requested.
Post-launch we run your monthly tax filings, quarterly LKPM (Investment Activity Reports), annual general meeting (RUPS), and any sector-specific reporting. You get a single point of contact and a monthly compliance digest — no Indonesian-language paperwork on your desk.
Status terkini, fokus regulasi, dan kaitannya dengan izin sektoral PB UMKU di bawah. Klik peraturan untuk membuka ringkasan plain-English.
› Pharmaceuticals — Phase 3 mandatory halal certification (Oct 2029 deadline)
› Pharmaceutical raw materials are recognized as a pioneer industry eligible for tax holiday.
› Mandatory halal certification applies to pharmaceutical products.
› This code involves pharmaceutical products that require halal certification for market entry.
Penjelasan sederhana tentang klasifikasi ini dan jenis usaha yang termasuk di dalamnya.
KBLI 21011 adalah kode Klasifikasi Baku Lapangan Usaha Indonesia 5-digit untuk pharmaceutical ingredients for humans. Termasuk dalam kategori Manufacturing Industry di bawah subgolongan Pharmaceutical and Chemical Medicinal Product Industry (golongan pokok 21) dalam taksonomi resmi KBLI 2020 yang dikelola Badan Pusat Statistik (BPS).
Setiap entitas, baik milik Indonesia maupun asing, yang berniat beroperasi di bidang pharmaceutical ingredients for humans sebagai kegiatan usaha utama atau sekunder wajib memilih kode ini pada NIB (Nomor Induk Berusaha). Kode yang dipilih menentukan instrumen perizinan yang dibutuhkan, otoritas penerbit, dan kewajiban kepatuhan berkelanjutan.
Pendekatan Berbasis Risiko OSS Indonesia menggunakan kode KBLI untuk menentukan tiga hal: (1) apakah investasi asing diizinkan dan dengan batas berapa, (2) instrumen perizinan berbasis risiko yang dibutuhkan, dan (3) otoritas yang menerbitkan setiap instrumen. Memilih kode yang salah dapat menunda atau membatalkan izin Anda.
BPS Indonesia menerbitkan taksonomi KBLI 2025 baru pada awal 2025. OSS, BKPM, dan kementerian operasional belum mengadopsinya — KBLI 2020 tetap menjadi standar aktif untuk pendaftaran usaha. Berikut apa yang akan datang untuk kode spesifik ini.
KBLI 21011 mempertahankan nomor kode dan ruang lingkup yang sama dalam taksonomi baru. Deskripsi kegiatan, hierarki, dan tujuan penggunaan kode tetap dipertahankan.
Ketika OSS mengadopsi KBLI 2025, kami akan memigrasi entitas yang ada ke kode pengganti yang sesuai sebagai bagian dari layanan kepatuhan berkelanjutan — tidak diperlukan tindakan dari pihak Anda sekarang.
Bicara dengan spesialisIndonesia's OSS Risk-Based Approach assigns a separate risk level for each of the four business scales. The licensing instruments required (NIB, Standard Certificate, Operating License) are determined by the risk level. Foreign-owned entities (PT PMA) must register at the Large scale, so the rightmost column applies to most foreign investors.
KBLI 21011 (Pharmaceutical Ingredients for Humans) adalah kode Klasifikasi Baku Lapangan Usaha Indonesia 5-digit untuk pharmaceutical ingredients for humans. Termasuk dalam kategori Manufacturing Industry dalam taksonomi resmi KBLI 2020 yang dikelola Badan Pusat Statistik (BPS).
Ya — KBLI 21011 sepenuhnya terbuka untuk investasi asing. PT PMA dapat beroperasi dengan kepemilikan asing hingga 100%, tunduk pada persyaratan modal BKPM Reg. 5/2025 (IDR 2,5 miliar modal disetor + IDR 10 miliar+ komitmen per KBLI). Untuk PT lokal (100% WNI), KBLI ini juga terbuka tanpa pembatasan tambahan.
Tingkat risiko KBLI 21011 per skala usaha: Mikro High, Kecil High, Menengah High, Besar High. Perusahaan milik asing (PT PMA) wajib mendaftar di skala Besar.
NIB + Izin Operasional — KBLI 21011 berisiko Tinggi pada skala Besar. Izin Operasional memerlukan persetujuan substantif dari regulator sektor sebelum bisnis dapat beroperasi; siapkan waktu peninjauan multi-bulan dengan dokumen teknis. Selain itu, sertifikasi halal BPJPH wajib menurut UU 33/2014 (OTC pharma mandatory by October 2029) — Emerhub mengurus pengajuan BPJPH dan koordinasi audit LPH atas nama Anda. 3 izin sektoral PB UMKU juga berlaku tergantung kegiatan spesifik — lihat ringkasan persyaratan di bagian atas halaman.
Override regulator sektor: No fixed minimum, but GMP-compliant facility build typically IDR 50-100 billion+ disyaratkan oleh BPOM / Kemenkes berdasarkan PMK 26/2018 (Pelayanan Perizinan Berusaha Terintegrasi Sektor Kesehatan). Lebih tinggi dari default BKPM Reg. 5/2025 IDR 2,5 miliar; angka yang lebih tinggi berlaku.
Pendirian PT PMA umumnya 4-8 minggu: pengesahan AHU (1-2 minggu), penerbitan NIB via OSS (instan hingga 1 minggu), pembukaan rekening bank (2-4 minggu). Siklus perizinan untuk KBLI 21011 secara spesifik 7 hari pada skala usaha Besar.
Ya — KBLI 21011 ada dalam daftar industri perintis Tax Holiday (PMK 130/2020) di bawah Pharmaceutical raw materials. Layak pembebasan PPh Badan 5-20 tahun tergantung tingkat capex.
Otoritas tergantung profil investor. Untuk PMA: Menteri/Kepala Badan. Untuk skala UMK domestik: umumnya Gubernur (untuk lingkup Provinsi) atau Bupati/Wali Kota (lingkup Kabupaten/Kota). Pemetaan spesifik ada di §1 halaman ini.
Selain NIB, KBLI 21011 memiliki 3 izin PB UMKU di 2 regulator sektor: Pharmaceuticals (2), Industry & Materials (1). Sebagian besar operasi hanya membutuhkan 2-4 izin — rangkaian yang relevan tergantung aktivitas spesifik yang Anda jalankan; Emerhub memetakan subset yang tepat sebelum proses pengajuan.
KBLI dalam subgolongan yang sama 2101: 21012 (Pharmaceutical Products Industry for Humans); 21013 (Animal Pharmaceutical Industry); 21014 (Pharmaceutical Industry for Animals); 21015 (Medical Devices Industry in Subgroup 2101). Ini kegiatan yang berkaitan erat — lihat bagian kode terkait di bawah untuk daftar lengkap.